Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/38964
Title: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients
Author: Villafan-Bernal, J.R.
Llamas-Covarrubias, M.A.
Munoz-Valle, J.F.
Rivera-Leon, E.A.
Gonzalez-Hita, M.E.
Bastidas-Ramirez, B.E.
Gurrola-Diaz, C.M.
Armendariz-Borunda, J.S.
Sanchez-Enriquez, S.
Issue Date: 2014
Abstract: Background: The uncarboxylated osteocalcin (ucOC) has been described as a regulator of glucose metabolism in mice, and it is decreased in human type 2 diabetes mellitus (T2D). Although inversely correlated with serum glucose, insulin, and glycated hemoglobin, it is unclear if ucOC decrement is caused by diabetes or plays a role in the pathogen-esis and/or progression of the disease. Whatever the case may be, diabetes affects osteoblast gene expression, and possibly the proportion of ucOC over carboxylated OC (cOC). The association of ucOC/cOC index with glycemic status markers in patients with T2D has not been described before. Objective: The objective of this study was to assess the ucOC/cOC index and its relationship with glycemic status markers in patients with T2D. Methods: The ucOC/cOC index was determined by the quotient of ucOC and cOC serum levels in 80 T2D patients and 160 healthy subjects. The relationship between the ucOC/cOC index and glycemic status markers was evaluated. Results: The ucOC/cOC index was low and negatively correlated to fasting plasma glucose and homeostasis assessment-insulin resistance model in T2D patients. The odds ratio for T2D patients with an ucOC/cOC index below the cut-point obtained by receiver operating characteristic analysis was 12.64 (confidence interval, 5.75-27.77; P < 0.001). Conclusions: A value of ucOC/cOC index less than 0.3 is associated with markers of poor metabolic control in patients with T2D. Copyright " 2013 by The American Federation for Medical Research.",,,,,,"10.231/JIM.0000000000000015",,,"http://hdl.handle.net/20.500.12104/38964","http://www.scopus.com/inward/record.url?eid=2-s2.0-84896745872&partnerID=40&md5=32e7199086921916b4f8d648b4f63709
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=24113735",,,,,,"1",,"Journal of Investigative Medicine",,"33
36",,"62",,"Scopus
WOS
MEDLINE",,,,"Index Medicus;Adult;Biological Markers/bl [Blood];Blood Glucose/me [Metabolism];Cohort Studies;Cross-Sectional Studies;Diabetes Mellitus, Type 2/bl [Blood];Diabetes Mellitus, Type 2/di [Diagnosis];Female;Glycemic Index/ph [Physiology];Humans;Male;Middle Aged;Osteocalcin/bl [Blood]",,"Bone; Diabetes; Glucose; Insulin; Metabolism/General & Internal Medicine; Research & Experimental Medicine",,,,,,"A cut-point value of uncarboxylated to carboxylated index is associated with glycemic status markers in type 2 diabetes",,"Article" "40735","123456789/35008",,"Armendariz-Borunda, J., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico, OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Lyra-Gonzalez, I., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico; Medina-Preciado, D., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Gonzalez-García, I., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Martinez-Fong, D., Department of Physiology, Biophysics and Neurosciences, CINVESTAV, Mexico D.F., Mexico; Miranda, R.A., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Magaña-Castro, R., Cell Therapy and Technology, S.A. de C.V., Mexico D.F., Mexico; Peña-Santoyo, P., Cell Therapy and Technology, S.A. de C.V., Mexico D.F., Mexico; García-Rocha, S., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Bautista, C.A., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Godoy, J., OPD, Hospital Civil de Guadalajara, Guadalajara, Mexico; Flores-Montana, J., Faculty of Medicine, Autonomous University of Chihuahua, Chihuahua, Mexico; Floresvillar-Mosqueda, J., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico; Armendariz-Vazquez, O., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico; Lucano-Landeros, M.S., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico; Vazquez-Del Mercado, M., Institute for Rheumatology and Muscle- Skeletal Research, CUCS, University of Guadalajara, Guadalajara, Mexico; Sanchez-Parada, M.G., Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, Mexico",,"Armendariz-Borunda, J.
Lyra-Gonzalez, I.
Medina-Preciado, D.
Gonzalez-García, I.
Martinez-Fong, D.
Miranda, R.A.
Magana-Castro, R.
Pena-Santoyo, P.
García-Rocha, S.
Bautista, C.A.
Godoy, J.
Flores-Montana, J.
Floresvillar-Mosqueda, J.
Armendariz-Vazquez, O.
Lucano-Landeros, M.S.
Vazquez-Del Mercado, M.
Sanchez-Parada, M.G.",,"2012",,"Background: Pathologic skin scarring reversion remains a big challenge for surgeons, as disfiguring scars have a dramatic influence on patient's quality of life. Methods: A controlled clinical trial was conducted to evaluate 8% pirfenidone (PFD) gel administered topically 3 times a day during 6 months to 33 pediatric patients with hypertrophic scars caused by burns. A total of 30 patients with hypertrophic scars with identical Vancouver Scar Scale values were treated with pressure therapy and included as controls. Improvements were evaluated by Vancouver Scar Scale and a Visual Analog Scale. Safety parameters were determined by the presence of adverse events and monitoring laboratory and hematology parameters. Results: Patients treated with PFD during 6 months presented a continuous monthly statistically significant scar regression in comparison with the initial Vancouver measurement (P = <0.001). PFD group showed a higher improvement of all scar features as compared with control group treated with pressure therapy (P = <0.001). In the PFD group, 9 of 33 patients (27%) had their scores decreased in Vancouver classification by more than 55%, 22 patients (67%) had a 30% to 45% decrease, whereas 2 patients (6%) had a 30% decrease or less. Control group treated with pressure therapy showed a slight improvement in 16% of cases on an average. Patients did not show serious adverse effects or laboratory alterations throughout the study. Conclusions: Topical administration of 8% PFD gel 3 times a day is more effective and safe in the treatment of hypertrophic scars caused by burns in children, as compared with standard pressure therapy. " 2012 by Lippincott Williams & Wilkins.
URI: http://hdl.handle.net/20.500.12104/38956
http://www.scopus.com/inward/record.url?eid=2-s2.0-84855202918&partnerID=40&md5=0b8d6130153be90887e0a79704d83686
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=21659848
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.